The new bill, which needs 10 Republican votes on top of the Democratic majority in the Senate to pass, would cap the monthly expense in insulin to $35—for insured patients, that is.

A lower copay (if you can get it)

The Affordable Insulin Now act, if approved by the Senate, could make a difference for about 20% of the privately insured Americans who currently spend more than $35 a month on their copay for the medication.

The bill would limit the out-of-pocket payment for insulin to a maximum of $35 per 30 days of treatment, or 25% of the price negotiated by the drug company with the insurance, whichever is lowest. No deductible could be applied for insulin.

The bill does nothing to actually stop price gauging and bring the price of insulin under control. It simply limits the monthly copay insurance companies can ask for. This means that the act has virtually no impact on the price of the drug for uninsured or underinsured patients (who, for instance, have insurance only for medical emergencies). Further, by forcing insurance companies to potentially pay a higher share of the drug, it could lead to higher premiums.

More comprehensive prescription drug legislation that would extend insulin coverage to uninsured patients, as well as allow Medicare to directly negotiate with pharmaceutical companies, lowering drug costs, and introduce other cost-cutting measures has been stalled in the Senate. The fate of it depends on the rest of the $2.2 trillion safety net package which has been stuck in the Senate for several months.

📬 Sign up for the Daily Brief

Our free, fast, and fun briefing on the global economy, delivered every weekday morning.